Literature DB >> 26508767

Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience.

Nat Wright1, Oscar D'Agnone2, Peter Krajci3, Richard Littlewood4, Hannu Alho5, Jens Reimer6, Carlos Roncero7, Lorenzo Somaini8, Icro Maremmani9.   

Abstract

BACKGROUND: Opioid dependence treatment, comprising opioid substitution treatment (OST) and psychosocial intervention, is accepted to improve outcomes in opioid addiction for both the individual and public health. OST medication such as methadone or buprenorphine may be misused or diverted. This results in failure to recover from addiction, increased crime and the spread of blood-borne viruses. Worldwide, attempts to address misuse and diversion have been proposed and implemented with varying impact.
METHODS: A structured, expert-led process recommended the most impact. As an initial step, a broad range of strategies were defined, and a systematic review of published literature identified 37 highly relevant sources of evidence. Experts reviewed this evidence and ranked the list of strategies for effectiveness and ease of implementation, based on their clinical experience. RESULTS/
CONCLUSIONS: Three groups of strategies to address misuse or diversion are defined, depending on impact (effectiveness and ease of implementation). Preferred strategies include the promotion of access to treatment and the use of product formulations less likely to be misused. However, additional data and innovative approaches to address this complex problem are needed.
© The Author 2015. Published by Oxford University Press on behalf of Faculty of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  diversion; misuse; opioid addiction; opioid substitution treatment (OST); strategy; treatment outcomes

Mesh:

Substances:

Year:  2015        PMID: 26508767     DOI: 10.1093/pubmed/fdv150

Source DB:  PubMed          Journal:  J Public Health (Oxf)        ISSN: 1741-3842            Impact factor:   2.341


  5 in total

1.  The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety.

Authors:  Jermaine D Jones; Adam Bisaga; Verena E Metz; Jeanne M Manubay; Shanthi Mogali; Roberto Ciccocioppo; Gabriela Madera; Molly Doernberg; Sandra D Comer
Journal:  J Psychoactive Drugs       Date:  2018-09-11

Review 2.  Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine.

Authors:  Florence Noble; Nicolas Marie
Journal:  Front Psychiatry       Date:  2019-01-18       Impact factor: 4.157

3.  Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.

Authors:  Michael Frost; Genie L Bailey; Nicholas Lintzeris; John Strang; Adrian Dunlop; Edward V Nunes; Jakob Billeskov Jansen; Lars Chemnitz Frey; Bernd Weber; Paul Haber; Sonia Oosman; Sonnie Kim; Fredrik Tiberg
Journal:  Addiction       Date:  2019-06-03       Impact factor: 6.526

4.  Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.

Authors:  Eugenia Oviedo-Joekes; Scott MacDonald; Charles Boissonneault; Kelli Harper
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-03-05

5.  Opiate agonist treatment to improve health of individuals with opioid use disorder in Lebanon.

Authors:  Ali Ghaddar; Zeinab Abbas; Ramzi Haddad
Journal:  Harm Reduct J       Date:  2017-12-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.